CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

[1]  T. Haferlach,et al.  IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. , 2010, Blood.

[2]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[3]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[4]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[5]  J. Goldman,et al.  Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? , 2006, Leukemia & lymphoma.

[6]  T. Holyoake,et al.  Punish the parent not the progeny. , 2005, Blood.

[7]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[8]  H. Kantarjian,et al.  Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.

[9]  M. Baccarani,et al.  Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. , 2004, Blood.

[10]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[11]  Judy Lieberman,et al.  Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. , 2003, Vaccine.

[12]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[13]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[14]  P. Parham,et al.  Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. , 1982, Journal of immunology.

[15]  E. Hitchman,et al.  Nucleolar Proteins B 23 and C 23 as Target Antigens in Chronic Graft-Versus-Host Disease , 2003 .

[16]  A. D. De Groot,et al.  Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. , 2003, Developments in biologicals.